Animal models of α-synucleinopathy for Parkinson disease drug development.
about
Enteric nervous system manifestations of neurodegenerative disease.MicroRNAs in Parkinson's disease and emerging therapeutic targets.New developments in genetic rat models of Parkinson's disease.Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice.Modeling Parkinson's Disease in Drosophila: What Have We Learned for Dominant Traits?Astrocytes, Microglia, and Parkinson's Disease.Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy.Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem CellsSynaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease modelsQuality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease
P2860
Q47845191-740D59BB-2308-4DED-A6E1-A17353684EF4Q47870847-9BE0F9AA-0AC0-43E6-A469-634AB57C690AQ48502440-E3F75064-9163-4FCD-B039-9EEC41F942F4Q50056490-96FA012A-EC1F-4E4F-9B2E-810891955876Q54114687-FECC4A0D-072E-4306-ADF9-41534CD1F970Q55000928-B189CF29-78B9-4D14-A7A3-17B8C78EC7B7Q55691017-7B66A2EC-F3F9-4DFE-B383-1E9DA0E8B718Q58726898-426BABE0-B18B-453A-A968-4018E17C8F01Q58762401-DC7F884E-D6E7-4BA6-9C88-2BEAC2FD9D78Q58764665-0DDFA2F4-E841-4478-9AF1-FD539B13B446
P2860
Animal models of α-synucleinopathy for Parkinson disease drug development.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Animal models of α-synucleinopathy for Parkinson disease drug development.
@en
type
label
Animal models of α-synucleinopathy for Parkinson disease drug development.
@en
prefLabel
Animal models of α-synucleinopathy for Parkinson disease drug development.
@en
P2860
P356
P1476
Animal models of α-synucleinopathy for Parkinson disease drug development.
@en
P2093
James B Koprich
Lorraine V Kalia
P2860
P2888
P304
P356
10.1038/NRN.2017.75
P407
P577
2017-07-13T00:00:00Z
P6179
1090652161